Stephen Rubino

Stephen Rubino

Chief Executive Officer at
Sporos Bioventures, Inc.
67 year
Health Technology
Consumer Services
Health Services

Profile

Stephen Rubino is currently the President, Chief Executive Officer & Director at Sporos Bioventures LLC and a Director at Sermonix Pharmaceuticals LLC.
He previously served as a Director at ILKOS THERAPEUTICS, Inc. from 2017 to 2020, an Independent Director at Viracta Therapeutics, Inc. from 2021 to 2024, the Head-Global Solid Tumor at Schering-Plough Europe SA from 1991 to 2001, and the Global Head-Business Development at Novartis Pharmaceuticals Corp.
from 2001 to 2017.
He also held the position of Chief Business Officer at Celyad Oncology SA from 2020 to 2022 and Chief Business & Strategy Officer at Omega Therapeutics, Inc. from 2018 to 2019.
Dr. Rubino holds an MBA from Baruch College and a doctorate from Weill Cornell Medical College.

Stephen Rubino active positions

CompaniesPositionStart
Director/Board Member -
Chief Executive Officer -

Former positions of Stephen Rubino

CompaniesPositionEnd
VIRACTA THERAPEUTICS, INC. Director/Board Member 30/10/2024
CELYAD ONCOLOGY SA Corporate Officer/Principal 31/03/2022
Director/Board Member 31/01/2020
OMEA THER Corporate Officer/Principal 30/04/2019
Corporate Officer/Principal 31/12/2016
See the detail of Stephen Rubino's experience

Training of Stephen Rubino

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

Connections

80

1st degree connections

10

1st degree companies

Male

Female

Members of the board

Executives

Linked companies

Private companies10
Schering-Plough Europe SA

Consumer Services

Health Technology

Health Technology

Consumer Services

Health Technology

Health Technology

Health Technology

Health Services

Health Technology

  1. Stock Market
  2. Insiders
  3. Stephen Rubino
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!